Neuspera Medical Announces Final Close of $26M Series B Equity Financing

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, today announced the final closing (2nd tranche) of the company’s Series B equity financing.

Neuspera Medical reports the final $12 million dollar tranche of the total $26 million round was triggered upon fulfillment of pre-defined product development and regulatory program objectives.  Each of the original Series B investors participated in the 2nd tranche – including 6 Dimensions Capital, Action Potential Venture Capital, Windham Venture Partners, Delta Capital, LLC, Purple Arch Ventures and others.  The proceeds will be used to advance the Company’s clinical programs for its implantable neuromodulation technology platform.

Neuspera Medical Inc. is a medical device company that leverages both exclusively licensed and proprietary power transfer techniques to engineer miniaturized neuromodulation technologies – sometimes referred to as bioelectronics medicines.  Neuspera’s hermetically sealed implantable modules are more than 100 times smaller than neuromodulation devices using a traditional implanted battery power source and may reduce implant procedure complexity, patient complication, and post-surgical pain.

“The Neuspera team has executed well against its milestones for this final tranche of funding for Series B,” said Dr. Zhu, Managing Partner of 6 Dimensions Capital.  “We continue to see the Neuspera platform as an important conduit to bringing the benefits of implantable medical device treatments to patients suffering from many chronic diseases earlier in their treatment cycle.”

“We have been keeping pace with our primary objective to bring forward the beneficial outcomes of neuromodulation treatment to more patients struggling with chronic and debilitating diseases,” said Milton M. Morris, Ph.D., President & CEO of Neuspera.  “We continue to see broad support and interest in our program as we effort to bring this technology forward to improve patient care and outcomes.”

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.